<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ose Immunotherapeutics Sa — News on 6ix</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa</link>
<description>Latest news and press releases for Ose Immunotherapeutics Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 05:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ose-immunotherapeutics-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d535b0beedb30cb6f6ee5e.webp</url>
<title>Ose Immunotherapeutics Sa</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa</link>
</image>
<item>
<title>OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopir-in-ovarian-cancer-at-the-asco-2026-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopir-in-ovarian-cancer-at-the-asco-2026-meeting-1</guid>
<pubDate>Thu, 23 Apr 2026 05:30:00 GMT</pubDate>
<description>Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO</description>
</item>
<item>
<title>OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-to-present-a-novel-first-in-class-fpr2-agonist-monoclonal-antibody-in-the-resolution-of-chronic-inflammation-at-the-aai-2026-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-to-present-a-novel-first-in-class-fpr2-agonist-monoclonal-antibody-in-the-resolution-of-chronic-inflammation-at-the-aai-2026-meeting-1</guid>
<pubDate>Wed, 15 Apr 2026 05:30:00 GMT</pubDate>
<description>Nantes, France, April 15, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that an abstract on a novel agonist monoclonal antibody targeting FPR2, a key receptor involved in the triggering resolution of inflammation, has been selected for an oral presentation at the 2026 Annual Meeting of the American Association of Immunolo</description>
</item>
<item>
<title>OSE Immunotherapeutics Evolves its Leadership Team</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-evolves-its-leadership-team-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-evolves-its-leadership-team-1</guid>
<pubDate>Tue, 14 Apr 2026 16:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today provided a Senior Management update. Following the confirmation of Marc Le Bozec as Chief Executive Officer on March 10, the Company i</description>
</item>
<item>
<title>OSE Immunotherapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-to-present-at-upcoming-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-to-present-at-upcoming-investor-conferences-1</guid>
<pubDate>Mon, 23 Mar 2026 17:00:00 GMT</pubDate>
<description>Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announces its participation in the following investor conferences: Mardi de la Bourse – Lyon Pôle Bourse (retail event)April 7, 2026 – CRCC Lyon, France Marc Le Bozec, Chief Executive Officer, will present the Company and meet with wealth managers, financial adv</description>
</item>
<item>
<title>OSE Immunotherapeutics Announces its 2026 Financial Calendar</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-its-2026-financial-calendar-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-its-2026-financial-calendar-1</guid>
<pubDate>Mon, 16 Mar 2026 06:30:00 GMT</pubDate>
<description>Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. InformationDate* 2025 Full-Year Financial Update and StatementsApril 29, 20262026 1Q Cash PositionApril 30, 2026Annual General MeetingJune 24, 20262026 First-Half Financial Update and StatementsSeptember 28, 20262026 3Q Cash PositionOctober 27, 20262026 4Q Cash PositionJanuary 26, 2027 * This financial calendar is provided for information only</description>
</item>
<item>
<title>OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-confirms-marc-le-bozec-as-chief-executive-officer-to-lead-next-phase-of-strategic-growth-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-confirms-marc-le-bozec-as-chief-executive-officer-to-lead-next-phase-of-strategic-growth-1</guid>
<pubDate>Tue, 10 Mar 2026 06:30:00 GMT</pubDate>
<description>Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately. Mr. Le Bozec had served as interim CEO since October 2, 2025. Following a thorough review of internal and external candidates and upon recommendation of the Nomination and Compensation Committee, the Board of Directors unanimously confirmed Marc Le Bozec's transition from</description>
</item>
<item>
<title>OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-accelerates-strategic-refocusing-to-advance-late-stage-value-drivers-lusvertikimab-and-tedopir-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-accelerates-strategic-refocusing-to-advance-late-stage-value-drivers-lusvertikimab-and-tedopir-1</guid>
<pubDate>Mon, 02 Mar 2026 17:00:00 GMT</pubDate>
<description>Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframeFocused investment on high‑value late‑stage assets Lusvertikimab and Tedopi® Multiple clinical catalysts expected from 2026 to 2028 Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR001212</description>
</item>
<item>
<title>OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-evaluating-tedopir-in-non-small-cell-lung-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-evaluating-tedopir-in-non-small-cell-lung-cancer-1</guid>
<pubDate>Thu, 26 Feb 2026 17:00:00 GMT</pubDate>
<description>NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second positive recommendation for the ongoing pivotal Phase 3 ARTEMIA trial evaluating Tedopi® in advanced non-small cell lung cancer (NSCLC). The IDMC advised that the study should continue as planned, with no protocol changes. In line with the predefined study oversight plan, the IDMC, composed of independe</description>
</item>
<item>
<title>OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-selects-chronic-pouchitis-and-hidradenitis-suppurativa-as-new-key-indications-for-lusvertikimab-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-selects-chronic-pouchitis-and-hidradenitis-suppurativa-as-new-key-indications-for-lusvertikimab-1</guid>
<pubDate>Thu, 29 Jan 2026 06:30:00 GMT</pubDate>
<description>OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationaleChronic Pouchitis offers a capital-efficient rare-disease path with fast route to marketHidradenitis Suppurativa enables rapid proof-of-concept in a large dermatology marketFirst Phase 2 clinical trial expected to start in H2 2026, subject to financingUlcerative Colitis remains a key indication to be partnered Nantes, France,</description>
</item>
<item>
<title>OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-unveils-2026-2028-strategic-plan-with-four-opportunities-for-value-creation-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-unveils-2026-2028-strategic-plan-with-four-opportunities-for-value-creation-1</guid>
<pubDate>Tue, 09 Dec 2025 06:30:00 GMT</pubDate>
<description>OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for LusvertikimabSubcutaneous formulation and combination strategies for Lusvertikimab in UCManagement webcast on Wednesday, December 10th at 6pm CET Nantes, France, December 9, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its new three-year strat</description>
</item>
<item>
<title>OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-strategic-amendment-to-abbvies-partnership-on-abbv-230-development-2</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-strategic-amendment-to-abbvies-partnership-on-abbv-230-development-2</guid>
<pubDate>Mon, 08 Dec 2025 06:30:00 GMT</pubDate>
<description>OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati</description>
</item>
<item>
<title>OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-positive-recommendation-from-independent-data-monitoring-committee-idmc-to-continue-pivotal-phase-3-artemia-trial-evaluating-tedopir-in-non-small-cell-lung-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-announces-positive-recommendation-from-independent-data-monitoring-committee-idmc-to-continue-pivotal-phase-3-artemia-trial-evaluating-tedopir-in-non-small-cell-lung-cancer-1</guid>
<pubDate>Mon, 17 Nov 2025 17:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer NANTES, France, November 17, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, today announced that the Independent Data Monitoring Committee (IDMC) overseeing the Compan</description>
</item>
<item>
<title>OSE Immunotherapeutics Reports First Half 2025 Financial Results</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-reports-first-half-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-reports-first-half-2025-financial-results-1</guid>
<pubDate>Wed, 15 Oct 2025 17:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025. The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025. 2025 Half-Year Financial Results (IFRS) In million eurosH1 2024H1 2025R</description>
</item>
<item>
<title>Appointment of Marc Le Bozec as Interim CEO</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/appointment-of-marc-le-bozec-as-interim-ceo-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/appointment-of-marc-le-bozec-as-interim-ceo-1</guid>
<pubDate>Fri, 03 Oct 2025 06:00:00 GMT</pubDate>
<description>Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors. The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer. The Board of Directors has empowered Marc Le Bozec to lead a</description>
</item>
<item>
<title>Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/full-renewal-of-the-board-of-directors-election-of-dr-markus-cappel-as-chairman-of-the-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/full-renewal-of-the-board-of-directors-election-of-dr-markus-cappel-as-chairman-of-the-board-of-directors-1</guid>
<pubDate>Tue, 30 Sep 2025 17:30:00 GMT</pubDate>
<description>Full renewal of the Board of DirectorsElection of Dr. Markus Cappel as Chairman of the Board of Directors Nantes, September 30, 2025, 7:30 p.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) held its Annual General Meeting today in Paris and welcomed the participation of shareholders in this key moment for the company’s future. The shareholders who voted on the resolutions represented approximately 56% of OSE’s share capital and more than 62% of the voting rights. During this G</description>
</item>
<item>
<title>OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-inserm-transfert-and-nantes-university-announce-strategic-partnership-to-accelerate-innovation-in-immunotherapy-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-inserm-transfert-and-nantes-university-announce-strategic-partnership-to-accelerate-innovation-in-immunotherapy-1</guid>
<pubDate>Fri, 26 Sep 2025 05:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the field</description>
</item>
<item>
<title>OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-publie-sa-position-de-tresorerie-au-30-juin-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-publie-sa-position-de-tresorerie-au-30-juin-2025-1</guid>
<pubDate>Thu, 25 Sep 2025 16:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025 Nantes, France, September 25, 2025, 6 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025. Update on AbbVie Partnership rel</description>
</item>
<item>
<title>Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/correction-of-a-material-error-relating-to-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/correction-of-a-material-error-relating-to-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital-1</guid>
<pubDate>Wed, 24 Sep 2025 06:00:00 GMT</pubDate>
<description>Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) corrects the information relating to the total number of shares and voting rights comprising its share capital. As part of the preparation for the General Meeting on September 30, 2025, OSE identified a processing error r</description>
</item>
<item>
<title>Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/two-international-proxy-advisory-firms-support-the-governance-project-proposed-by-ose-immunotherapeutics-at-the-september-30th-general-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/two-international-proxy-advisory-firms-support-the-governance-project-proposed-by-ose-immunotherapeutics-at-the-september-30th-general-meeting-1</guid>
<pubDate>Mon, 22 Sep 2025 06:00:00 GMT</pubDate>
<description>Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that two international proxy advisory firms, including Glass Lewis, recommend shareholders to vote IN FAVOR of the resolutions proposed by the Board of Directors regarding its composition (resolutions 5 to 8) at the general meeting of</description>
</item>
<item>
<title>OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer</title>
<link>https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-and-the-fort-foundation-announce-completion-of-enrollment-in-combi-ted-a-phase-2-clinical-trial-evaluating-tedopir-in-combination-with-nivolumab-or-docetaxel-in-patients-with-non-small-cell-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/ose-immunotherapeutics-sa/news/ose-immunotherapeutics-and-the-fort-foundation-announce-completion-of-enrollment-in-combi-ted-a-phase-2-clinical-trial-evaluating-tedopir-in-combination-with-nivolumab-or-docetaxel-in-patients-with-non-small-cell-cancer-1</guid>
<pubDate>Thu, 11 Sep 2025 16:00:00 GMT</pubDate>
<description>OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer A total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line treatment for metastatic Non-Small Cell Lung Cancer following first-line chemo-immunot</description>
</item>
</channel>
</rss>